Gut microbiota and intestinal permeability in rheumatoid arthritis: therapeutic implications and future directions
4 affiliations
- 1Department of Biomechanics and Kinesiology, Chair of Biomedical Sciences, Institute of Physiotherapy, Faculty of Health Sciences, Jagiellonian University Medical College
- 2Department of Internal and Agricultural Medicine, Faculty of Medicine, Jagiellonian University Medical College
- 3Chair of Biomedical Sciences, Institute of Physiotherapy, Faculty of Health Sciences, Jagiellonian University Medical College
- 4Department of Medical Physiology, Chair of Biomedical Sciences, Institute of Physiotherapy, Faculty of Health Sciences, Jagiellonian University Medical College
Abstract
Interactions between the intestinal microbiota, epithelial barrier and mucosal immune system have prompted investigation of gut-directed interventions in rheumatoid arthritis (RA). This review examines whether modifying these interactions can improve clinical outcomes and assesses the strength of the available evidence in RA. In experimental arthritis, interventions that preserve epithelial integrity or alter microbial metabolism can reduce disease severity, providing a biological basis for further study. However, their relevance to human RA remains uncertain, since effects observed in animal models do not establish clinical efficacy, and changes in intestinal measurements alone do not demonstrate improvement in joint disease. Future controlled trials should assess disease activity, and physical function alongside microbial composition and function, intestinal measurements and immune responses. Repeated sampling may help establish whether intestinal changes precede or accompany clinical improvement, while recording medication exposure and dietary intake is needed to interpret these relationships. Candidate biomarkers will require prospective validation before they can be used to select patients for treatment. These studies should determine whether gut-directed interventions provide additional clinical benefit, in whom, and at what risk.
Related
- Targeted Quantitative Polymerase Chain Reaction Analysis of Gut Microbiota and Its Association With Feeding and Mealtime Behavior and Intestinal Permeability in Children With Autism Spectrum Disorder
- Macrophage lipid metabolism and inflammasome activation in rheumatoid arthritis: emerging mechanisms and therapeutic implications
- The Crosstalk Role of Intestinal Barrier Damage in the Gut-Organ Axis and its Potential Therapeutic Implications.
- Gut microbiota in esophageal cancer: mechanisms, clinical implications, and therapeutic potential
- Crosstalk between gut microbiota-associated metabolites and adaptive immunity in cholecystitis: a conceptual mechanistic framework and potential therapeutic implications
BibTeX
@article{bilski2026microbiota,
title = {{Gut microbiota and intestinal permeability in rheumatoid arthritis: therapeutic implications and future directions}},
author = {Jan Bilski and Agata I. Schramm-Luc and Marian Szczepanik and Piotr Pierzchalski and Kevin Luc},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1936364},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1936364/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Gut microbiota and intestinal permeability in rheumatoid arthritis: therapeutic implications and future directions
AU - Jan Bilski
AU - Agata I. Schramm-Luc
AU - Marian Szczepanik
AU - Piotr Pierzchalski
AU - Kevin Luc
PY - 2026
DA - 2026/10/14
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1936364
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1936364/full
AB - Interactions between the intestinal microbiota, epithelial barrier and mucosal immune system have prompted investigation of gut-directed interventions in rheumatoid arthritis (RA). This review examines whether modifying these interactions can improve clinical outcomes and assesses the strength of the available evidence in RA. In experimental arthritis, interventions that preserve epithelial integrity or alter microbial metabolism can reduce disease severity, providing a biological basis for further study. However, their relevance to human RA remains uncertain, since effects observed in animal models do not establish clinical efficacy, and changes in intestinal measurements alone do not demonstrate improvement in joint disease. Future controlled trials should assess disease activity, and physical function alongside microbial composition and function, intestinal measurements and immune responses. Repeated sampling may help establish whether intestinal changes precede or accompany clinical improvement, while recording medication exposure and dietary intake is needed to interpret these relationships. Candidate biomarkers will require prospective validation before they can be used to select patients for treatment. These studies should determine whether gut-directed interventions provide additional clinical benefit, in whom, and at what risk.
SN - 1664-3224
ER -